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INTRODUCTION:
Collagen synthesis and collagen degradation take place in a strictly 
controlled state of equilibrium. Loss of this equilibrium, results in 
abnormal tissue repair.  Excessive collagen synthesis and / or degradation 
may lead to one of the most challenging sequels in the clinical practice.
Keloid scars are one of the most challenging problems for physicians and 
surgeons. These scars have been treated in many ways with varying 
success. In our study, we are comparing 5 different treatment modalities 
in the management of keloid.
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REVIEW OF LITERATURE:
DEFINITION OF A SCAR:
A scar can be defined as a macroscopic disturbance of the normal 
structure and function of the skin resulting from the end product of a 
healed wound.
NORMAL PROCESS OF WOUND HEALING:
Wound healing is a natural restorative response to tissue injury. It has 3 
classic phases. A) Inflammation B) Proliferation C) Maturation.
Proliferation includes a) Epithelisation b) Fibroplasia c) Angiogenesis
INFLAMMATION:  Wounding of skin disrupts tissue and blood vessels 
leading to a direct exposure of extracellular matrix to platelets. Platelets 
release cytokines like PDGF, TGF –β, serotonin and fibronectin. A fibrin 
clot is formed which acts as a scaffold for neutrophils, monocytes, 
macrophages and lymphocytes which release a number of cytokines.
PROLIFERATION: There is a proliferation of fibroblasts and 
endothelial cells due to the action of VEGF and TGF-β. Early granulation 
tissue is formed which is characterised by myofibroblasts that contain 
elevated levels of α smooth muscle actin. Then there is proliferation and 
migration of epithelial cells adjacent to the wound.
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MATURATION:  This is characterised by reorganization of collagen. 
Early matrix is composed of fibronectin and collagen type 3 which is 
replaced by final matrix which is composed of glycosaminoglycans, 
proteoglycans and collagen type 11.
CLASSIFICATION OF SCARS:
Fine line scars: Eg: surgical scars.
Wide stretched scars: Eg: Abdominal striae of pregnancy.
Atrophic scars: Eg. Chicken pox scars.
Scar contractures: Eg. Burn injury.
Raised skin scars:
A) Hypertrophic scars – raised scars that remain within the boundaries 
of the wound.
B) Keloidal scars – raised scars that spread beyond the boundaries of 
the wound.
Intermediate scars: scars which are difficult to categorize2
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KELOID:
DEFINITION:
A keloid may be defined as a benign growth of fibrous tissue developing 
from an abnormal healing response to a cutaneous injury, extending 
beyond the original borders of the wound or inflammatory response3.
EPIDEMIOLOGY:
INCIDENCE: The epidemiology of keloids is variable. The reported 
incidence in the general population ranges from a high of 16%4 in Zaire 
among adults to a low of 0.09% in England4.
AGE AND SEX DISTRIBUTION: Keloids are more common in the age 
group of 10 to 30 years5. Mean age of keloid diagnosis in males is 22.8 
years and in females is 22.3 years. Sex incidence is equal5.
HISTORY:
Keloids were first described in an Egyptian papyrus6 about 1700 b.c. Jean 
Louis Alibert6 (1768-1837) described these lesions in 1806 and called 
them “cancroide”. To avoid confusion with cancer, he changed the name 
to “cheloide”. The word is derived from the Greek “chele” meaning 
“crab’s claw” and the suffix “oid” meaning “like”.
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Yorubas6, a tribe from Nigeria had the custom of facial markings and ear 
piercing .They described the familial occurrence of keloids as early as 
800a.d.The Olmec tribe of Mexico6 in pre – Columbian times used keloid 
scarification as a means of decoration. The women of Nubia-kush in 
Sudan are intentionally scarified with facial keloids as a means of 
decoration.
ETIOLOGY:
The predisposing factors include: a) Trauma b) Skin tension c) Infection 
d)Autoimmune phenomenon e) Hormonal factors f) Genetic factors
f)Drugs g) Foreign material h) Racial factors i)Climate
TRAUMA: It is an important provoking factor. The following types of 
trauma have been implicated in the development of keloids. Incisions, 
abrasions, insect bites, chemical and thermal burns, scalds, vaccination 
(BCG& varicella)7, ear lobe piercing8, circumcision9 , coronary artery 
bypass surgery, waxing10, umbilical keloid 11 following cord separation, 
corneal keloid12 following surgery, intraoral keloid13 as a complication of 
forehead flap in the oral cavity, palmar keloid following release operation 
for Dupuytren’s contracture14,15.
INFECTION:  Infections like folliculitis, small pox, chicken pox16, may 
act as a precipitating factor for keloid formation. Some types of keloid are 
more prone for suppuration called as suppurative keloidosis17,18.
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SKIN TENSION: There are 2 contradictory theories explaining the role 
of skin tension in the development of keloid. One school of thought says 
that in areas of increased skin tension like the chest and the back, the 
prevalence of keloids is higher. Another theory proposed,contradicts the 
aforementioned one. It states that ear,inspite of having low skin tension 
has high prevalence of keloids. So the role of skin tension in keloid 
pathogenesis is not clearly defined yet. It has been observed that high 
tension is present in the edges and not in the centre of keloids. So healing
easily takes place in the centre and not in the edges. And the expansion of 
keloids is in the direction in which it is pulled19.
AUTOIMMUNE PHENOMENA: Following trauma, sebum is secreted 
intradermally. This sebum acts as an antigen to trigger an autoimmune 
granulomatous response. This is called sebum autoimmune hypothesis20.
HORMONAL FACTORS: Keloids exhibit a higher level of androgen
binding than surrounding normal tissues23. Upper chest, back are 
predisposed to keloid formation as they have a higher rate of 
dihydrotestosterone metabolism. So it is suggested that topical              
anti-androgens may play a role in therapy. Keloids are found to be 
associated with acromegaly, pregnancy21, hyperthyroidism22. This further 
supports the view that hormones are involved.
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GENETIC FACTORS:  Autosomal dominant inheritance with 
incomplete penetrance and variable expression24 has been suggested. 
Autosomal recessive inheritance has also been described. HLA 
associations include HLA B14, HLA B21, HLA DR5, HLA DQW325. 
Heterogeneity in the chromosomal loci 2q23 and 7p21 has been 
suggested. Patients with blood group A have increased tendency to form 
keloids38.
FOREIGN MATERIAL: Presence of foreign material either exogenous 
(suture material) or endogenous (embedded hair) may lead to keloid 
formation.
DRUGS: In athletes taking anabolic steroids, linear keloids26 have been 
reported. Isotretinoin given after dermabrasion or argon laser for acne or 
rosacea may delay wound healing and cause keloids27.
RACIAL FACTORS:   More common in blacks, Chinese, 
Afrocarribeans5. Blacks: Whites ratio is 15:1. This may be due to 
increased melanocyte stimulating hormone which can lead to keloid 
formation.
CLIMATE:   Europeans living in tropics form keloids more frequently 
than those living in temperate zones. This may suggest a role for climate 
in the etiology of keloids28
88
PATHOGENESIS:
The pathogenesis of keloid is complex. The balance between collagen 
synthesis and degradation is maintained by matrix metalloproteinases and 
tissue inhibitors of matrix metalloproteinases. This in turn is controlled by 
TGF - β. TGF- β is of three types 1, 2, 3. Increased levels of types 1& 2 
lead to keloid formation as it inhibits MMP’S and potentiates 
TIMP’S.TGF –β Type 3 is found to play a protective role antagonising the 
action of 1&2 types1. Mannose 6 phosphate also inhibits TGF-β types 
1&2. There are various other studies which suggest a role for 
Plasminogen – Plasmin system29 in the pathogenesis of keloid. Plasmin is 
found to activate TGF-β. Activin30, another protein of the TGF -β 
superfamily stimulates the proliferation of fibroblasts and hence plays an 
important role. Cytokines like IL-6, TNF α , were found to be increased in 
keloids31. So cytokines are thought to play a part in the evolution of 
keloids.
Recently a new theory called as the neurogenic inflammation hypothesis32
has been put forward. This states that mechanical stress stimulates 
nociceptors on sensory fibres in skin which release neuropeptides like 
substance P, CGRP, TGF -β which in turn activates fibroblasts.
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CLINICAL FEATURES:
Within 3 to 4 months of a provocative stimulus, keloids develop. The 
lesions are firm, pink, or red plaques which continue to grow for months 
or even years, and extend beyond the margins of the original lesion. They 
may assume a dumb bell shaped configuration or become bizarre and 
irregular. In ears, pedunculated forms are seen. Consistency ranges from 
soft and doughy to hard. The lesions can also undergo suppurative 
necrosis17,18. It can rarely ulcerate. Malignant degeneration such as 
squamous cell carcinoma has also been reported in the literature, though 
extremely rare33,99. The sites of occurrence vary among different racial 
groups. In decreasing order of frequency, these are:
Whites: face (cheeks, earlobes), upper extremities, chest, neck, back, 
lower extremities, breast, abdomen.
Blacks: face, lower extremities, breast, chest, back, abdomen.
Other sites involved are: Genitals –following circumcision or trauma.
Cornea – following surgery or trauma.
Umbilicus – following cord separation.
Palms – following release operation for Dupuytren’s
Contracture.
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Symptoms commonly observed are:  Pruritus (80%), pain (50%), burning 
sensation, limitation of movement (if present over joint).
HISTOPATHOLOGY OF KELOID:
Epidermis is normal.  There is no scarring of papillary dermis. Collagen 
bundles or whorls of collagen with peripheral capsule like band are 
present. These are stretched and aligned in the same plane as the 
epidermis. The centre of the lesion is relatively acellular. The collagen 
fibres are large, thick and hyalinised. A horizontal fibrous band is seen in 
the upper reticular dermis. There is a tongue like advancing edge beneath 
a normal epidermis and papillary dermis, in contrast to hypertrophic scars 
in which there is no advancing edge34.
BIOCHEMICAL CHARACTERISTICS:
Total collagen as measured by hydroxy proline estimation method is 
increased. Proteoglycan content measured by glucosamine estimation 
method is also found to be increased. Water content, measured as a 
difference between wet weight and dry weight of scar biopsies is found to 
be high in keloid. Keloids have higher acid collagen than pepsin soluble 
collagen. As pepsin soluble collagen represents cross linked collagen, 
cross linking is found to be defective in keloids35.
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DISTINGUISHING FEATURES:
FEATURE NORMAL 
SCAR
HYPERTROPHIC       
SCAR
KELOID
PEAK AGE OF 
ONSET Any age Any age 10 -30 years
RISK 
FACTORS
None Increased wound 
depth, size, 
tension, infection.
Dark skin, 
family history, 
blood       group 
A, hormones, 
site of injury
EXTENSION Never  extends 
beyond margins
Never extends 
beyond margins
Extends beyond 
the margins
TIME OF 
ONSET
< 4 weeks < 4 weeks 3 months to 
years
COURSE Full Resolution Partial resolution No resolution
HISTOLOGY No 
Myofibroblast, 
fine collagen.
Myofibroblast + , 
fine collagen
No 
Myofibroblast, 
thick  collagen36
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ASSOCIATIONS OF KELOID:
Dupuytren’s contracture, Ehlers Danlos syndrome, Rubinstein Taybi 
syndrome, Dubowitz syndrome, Pachydermoperiostosis, Geominne 
syndrome, Turner’s syndrome, Noonan’s syndrome, Acne conglobata, 
Hidradenitis suppurativa, Pilonidal cysts, Pseudofolliculitis barbae37.
DIAGNOSIS:
This is based on the typical morphology of the lesion. Histopathology and   
electron   microscopic examination can be done in doubtful cases.
DIFFERENTIAL DIAGNOSIS:
Hypertrophic scar: Lesions do not extend beyond the margins of the 
wound, there is a tendency for spontaneous resolution, biopsy shows
young thin collagen fibres, myofibroblasts are present.
Lobomycosis : Fungal infection caused by Lacacia loboi. Biopsy shows 
fungi, giant cells. Fungi are lemon shaped, joined to one another by a 
narrow tubular neck. The lesions are devoid of collagenous fibrosis.
Keloidal morphoea: Biopsy helps in differentiating the two. Thinned out 
epidermis, homogenised, hyalinised, hypertrophic collagen fibres are 
seen. The eccrine glands are seen high up in the dermis40.
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Dermatofibroma: The common site of involvement is limbs. Dimple 
sign will be positive. In biopsies, epidermis is hyperplastic, Grenz zone is 
seen. In the dermis proliferation of histiocytes, giant cells are seen.
Dermatofibrosarcoma protruberans: Common in females. Rapid 
growth is seen. Usually occurs as an irregular plaque which later develops 
nodules.HPE shows a storiform arrangement of spindle shaped cells42.
Keloidal granuloma faciale: More common in men. It is usually seen in 
the face as a reddish plaque with dilated follicular orifices. Biopsy shows 
a Grenz zone, and a vasculitic picture41.
Keloidal sarcoidosis: Involvement of other systems should be looked for.
Biopsy shows a naked granuloma with reticulin fibres. Asteroid and 
Schaumann bodies can be seen.
Lupus vulgaris: Can also present with a keloidal morphology. Biopsy 
shows the typical tuberculoid granuloma.
Erythema elevatum diutinum: This has a vasculitic picture on biopsy39.
Corneal keloid: Has to be differentiated from corneal neurofibroma, 
recurrent limbal dermoid12, corneal myxoma, corneal xanthoma.
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MANAGEMENT OF KELOID:
It should be based on three pronged approaches. It includes
1. Manipulation of the mechanical properties of wound repair.
2. Correction of the abnormal balance of collagen synthesis and 
degradation.
3. Alteration of the immune inflammatory response.
PREVENTION:
1. Pre-surgical evaluation of potentially high risk patients by clinically 
evaluating their previous surgical scars
2. Family history of keloids should be looked for.
3. Non essential cosmetic surgeries should be avoided in patients who 
are prone to keloids.
4. Adequate precautions should be taken during surgery such as 
proper orientation of incision lines (parallel to skin creases) to 
reduce wound tension.
5. Incision sites in the mid-chest or over the joints should be avoided 
as far as possible.
6. Avoid the use of buried absorbable sutures, and use of non-
absorbable sutures should be carried out.
7. Use of electrosurgical devices must be restricted.
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Treatment modalities available are as follows:
1. Compression therapy60,61.
2. Cryotherapy63,64,65.
3. Intralesional therapies:
a) Intralesional Triamcinolone acetonide67,68,69,70.
b) Intralesional 5- Fluorouracil71,72,73,74
c) Intralesional Verapamil75,76,77,78
d) Intralesional Interferons81,82
e) Intralesional Bleomycin79,80
4. Silicone gel sheets83,84.
5. Lasers :
a) Pulsed dye laser85,86
b) ND:YAG laser.87,88
c) Co2 laser90
d) Argon laser89
6. Surgical excision95,100.
7. Combination therapies:
a) Surgical excision can be combined with intraoperative and/or 
postoperative steroid injections97.
b) Surgical excision with postoperative Verapamil injections77.
c) Surgical excision followed by radiotherapy96.
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d) Intralesional 5- fluorouracil combined with Triamcinolone 
injection102,103,104.
e) Cryotherapy followed by Intralesional Triamcinolone and 
silicone gel sheets94.
8. Miscellaneous therapies:
a) Topical tamoxifen43,44 – Nonsteroidal antiandrogen  that 
decreases the expression of TGF- β.
b) Onion extract gel45.
c) Retinoic acid46,47 – reduction of fibroblast proliferation and 
collagen synthesis.
d) Putrescine 48- inhibits tissue transglutaminase that plays a role in 
collagen crosslinking.
e) Tranilast49
f) Botulinum toxin50.
g) Enalapril51.
h) Pentoxiphylline
i) Colchicine.
j) Tacrolimus.
k) Alloderm52(Acellular human dermis.)
l) Camptothecin 53 - inhibits collagen synthesis
m) Intralesional collagenase54.
n) Quercetin55.
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o) Intralesional Etanercept56.
p) Heparin57.
q) Green tea58.
r) Imiquimod59.
s) Creams containing extracts from plants such as Bulbine 
frutescens and Centenella asiatica.
COMPRESSION THERAPY:
This includes
a) Button compression.
b) Pressure ear rings.
c) Elastic adhesive bandages.
d) Zinc oxide adhesive bandages62
MECHANISM OF ACTION:
It decreases oxygen tension through occlusion of small vessels and 
subsequent reduction in tissue metabolism, fibroblast proliferation and 
collagen synthesis.
Capillary pressure greater than 4mm Hg is applied for > 23.5 hours / day. 
This has to be continued for 6 to 12 months. The disadvantages are 
thermal insulation and movement restriction60,61.
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CRYOTHERAPY:
It is a common modality which is used to treat hypertrophic scars and 
keloids. Substances which are used in cryotherapy are
a) Liquid nitrogen -   - 196 degree Celsius.
b) Ice   - 0 degree Celsius
c) Co2 slush -  - 20 degree Celsius
d) Co2 snow -  -79 degree Celsius
e) Nitrous oxide -  -90 degree Celsius
MECHANISM OF ACTION:
Destruction of keloidal fibroblasts by
a) Intracellular and extracellular ice formation.
b) Osmolarity changes.
c) Apoptosis.
d) Thermal shock.
e) Vascular changes.
f) Coagulation of proteins.
g) It also causes local edema and gives anaesthetic effect for 
subsequent injection of intralesional steroids.
Macroscopic changes observed after cryotherapy are that, during and 
immediately after the application, white ice field is formed. A minute 
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later, after thawing a purplish violet colour develops at periphery and 
moves centrally. And the deeper tissues become pale. In one or two days a 
hemorrhagic blister on an erythematous base develops in the centre. In a 
week, blister forms an eschar. Eschar separates spontaneously in 2 weeks.
SIDE EFFECTS:
Acute : pain, headache, edema, blister, fever, syncope.
Chronic : hypopigmentation, depigmentation, hyperpigmentation, milia, 
arthralgia, nerve damage, paraesthesia, atrophy63,64,65.
TECHNIQUES AVAILABLE:
a) Cryospray
b) Cryoroller.
c) Cryoprobe.
d) Intralesional cryosurgery66.
INTRALESIONAL CORTICOSTEROID INJECTION:
It is very widely used in the treatment of keloids. The preferred steroid is 
Triamcinolone acetonide. And it is used in a concentration of 10 to 40 mg/ 
ml, depending on the size and location of the lesion.
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METHOD OF ADMINISTRATION:
Triamcinolone acetonide 40 mg/ ml is injected alone or in combination 
with lignocaine 1%, with a 25 to 27 gauge needle attached to an insulin 
syringe. The needle is introduced into the lesion at an angle of 30 to 45 
degrees with bevel of the needle pointing downwards. Inject only after 
aspiration.0.05 to 0.1ml is injected at each site sequentially by multiple 
puncture technique, so as to cause blanching. Blanching should not be 
allowed to spread to the adjacent tissue. Pressure hemostasis is achieved 
and dressing with antibiotic ointment is given. Postoperatively antibiotics, 
analgesics, and anti- inflammatory drugs are given. The injections are 
given at intervals of 3 to 4 weeks.
MECHANISM OF ACTION:
a) Inhibits fibroblast growth.
b) Inhibits collagen and glycosaminoglycan synthesis.
c) Decreases TGF-β and increases basic- FGF production.
d) Decreases the release of inflammatory mediators.
e) Decreases alpha 2 macroglobulin levels (which inhibits 
collagenase).
f) Vasoconstrictive effect67,68,69,70
SIDE EFFECTS:
a) Pain during injection.
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b) Skin atrophy.
c) Depigmentation, hypopigmentation
d) Telangiectasia.
e) Necrosis and ulceration (rare)
f) Cushingoid symptoms98 (rare)
INTRALESIONAL 5 – FLOUROURACIL:
It is a pyrimidine analogue.
MECHANISM OF ACTION:
Inhibiting DNA synthesis by competing with Uracil incorporation. It is
postulated that it acts on fibroblasts and decreases its proliferation.
METHOD OF ADMINISTRATION:
5 – Flourouracil is available in a concentration of 50 mg/ml. It is given 
intralesionally alone or in combination with 1% lignocaine with a 25 to 27 
gauge needle attached to an insulin syringe. 0.05 to 0.1 ml is given at each 
site sequentially by multiple puncture technique to cover the the entire 
lesion. The injections are given at an interval of 1 or 2 weeks. In a single 
session, not more than 2ml should be given.
CONTRAINDICATIONS:
Pregnancy, lactation, infection, bone marrow suppression, liver and 
kidney disease.
22
22
SIDE EFFECTS:
Pain, burning sensation, ulceration, hyperpigmentation, necrosis71,72,73,74.
INTRALESIONAL VERAPAMIL INJECTION:
It is a calcium channel blocker.
MECHANISM OF ACTION:
They depolmerize actin filaments and alter the shape of fibroblasts from 
bipolar to spherical and thus results in increase in collagenase 
production75,76,77,78.
METHOD OF ADMINISTRATION:
It is available in a concentration of 2.5mg/ml. It is given with a 25 to 27 
gauge needle attached to an insulin syringe. 0.05 to 0.1ml is given at each 
site sequentially, and the entire lesion is covered. The injections are given 
at intervals of 3 weeks.
CONTRAINDICATIONS:
Hypotension, left ventricular dysfunction, sick sinus syndrome, atrial 
fibrillation, or flutter.
ADVANTAGES:
Verapamil, being a solution is much easier to inject intralesionally. It has 
less side effects compared to triamcinolone76.
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INTRALESIONAL BLEOMYCIN:
It is a chemotherapeutic agent used in many cancers.
MECHANISM OF ACTION:
a) Blockage of cell cycle
b) Degrading DNA and RNA.
c) Production of reactive oxygen species
MODE OF ADMINISTRATION:
Bleomycin tattooing or multiple puncture technique is used. Multiple 
punctures are made in the lesion and 1.5 IU/ ml of bleomycin is applied 
topically to these areas. About 40 punctures / mm2 are made. 3 to 5 
infiltrations are given in one month period.
SIDE EFFECTS:
Pain, hyperpigmentation , ulceration79,80.
INTRALESIONAL INTERFERONS:
Interferons alpha, beta, gamma can be used.
MECHANISM OF ACTION:
a) Increases collagenase activity.
b) Decreases fibroblast production of glycosaminoglycans.
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MODE OF ADMINISTRATION:
It is given at a dosage of 1 million units/cm2 of scar with a maximum of 5 
million units. It is given 3 times per week for 3 weeks.
SIDE EFFECTS:
Influenza like symptoms, nausea, diarrhoea, hypotension, tachycardia, 
dysarrythmia81,82.
SILICONE GEL SHEETS:
Silicones are synthetic polymers based on dimethyl siloxane monomer. 
They have a repeated structural unit Si0 (CH3)2. 3 types of silicones are 
used namely fluids, gels, elastomers.
MECHANISM OF ACTION:
It is postulated that it causes hydration and modulates the effect of 
keratinocytes on fibroblasts .Hydration is thought to result in decreased 
capillary activity with ultimate reduction in collagen deposition via 
decreased synthesis of pro -inflammatory cytokines. It is also thought to 
alter oxygen tension in tissues. Static electricity that develops at gel 
dressings and skin interface or the effect of temperature changes leads to 
blockage of growth factors which result in diminished fibroblast activity 
and collagen breakdown.
25
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MODE OF USAGE:
The sheet is trimmed from the standard sized sheet, so that it matches the 
specific scar. The sheet should extend atleast one to one and half inches 
around the lesion for a better hold. It is directly applied over the lesion 
and kept in place with a micropore tape. It is worn for 8 hours per day. 
Each sheet will last for 28 to 30 days83,84.
LASERS:
Lasers are also used in the management of keloids. The types of laser used 
are
a) Co2 laser (10,600nm)
b) Nd :YAG laser (1064nm)
c) Pulsed dye laser (585nm)
d) Argon laser (488nm)
PULSED DYE LASER:
It acts by selective thermolysis85,86. It is given in a dosage of 5 J/cm2.
ND: YAG LASER:
It has been suggested that Nd:YAG laser cause inhibition of collagen 
production. Dosage is 1.1*103 J /cm2. The disadvantage is that melanin in 
epidermis causes most of the laser energy to be absorbed at superficial 
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level, so little or no effect is seen on deeper tissues. Recurrence rate is 
between 53 – 100%87,88.
ARGON LASER:
It acts through photothermolysis. Has high level of recurrence (45 –
93%)89.
CO2 LASER:
Superpulsed CO2 laser energy can stimulate the release of basic –FGF 
and inhibits release of TGF- β in both normal and keloid cells. It is used in 
a dosage of 2.5 W /cm2. It has a high level of recurrence that varies 
between 25- 74%90.
SURGICAL EXCISION:
Surgical excision of keloid can either be done as keloid fillet flap method 
or keloid core excision95,100. It can also be combined with other modalities 
like intralesional triamcinolone97 or verapamil77 or along with 
radiotherapy96.
COMBINATION THERAPIES:
When compared to a single modality of treatment combination therapies 
are found to be very useful in the treatment of keloid. Intralesional  
triamcinolone and 5 – fluorouracil can be combined together and given 
once in 3 weeks. This gives a faster response when compared to 
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5 – fluorouracil given alone and also the side effects of 5 – FU can be 
avoided by this technique94.
Cryotherapy when combined with intralesional steroids aids in easy 
penetration of the drug due to the edema and also has a local anaesthetic 
effect for subsequent steroid injections.
Silicone gel sheets when combined with intralesional steroid injections 
were found to result in faster resolution of the scar102,103,104.
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AIM OF THE STUDY:
The aim of the study was
1. To study the efficacy of various modalities of treatment and to 
compare them with one another.
2. To study the adverse effects of the various modalities used.
3. To study the correlation between treatment response and the 
duration, size, number of lesions.
The different modalities of treatment used in this study were
1. Intralesional  Triamcinolone (40mg/ml)
2. Intralesional 5-Flourouracil   (50mg/ml)
3. Intralesional Verapamil(2.5mg/ml)
4. Combination of Intralesional Triamcinolone (40mg/ml)and 
Intralesional 5- Fluorouracil (50mg/ml)
5. Combination of Cryotherapy, Intralesional Triamcinolone and 
Silicone gel sheets.
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MATERIALS AND METHODS:
Study design: Prospective randomized open labelled clinical trial.
Patients presenting with keloid to the dermatology department of our 
hospital during the study period of August 2008 to August 2010 were 
recruited. A diagnosis of keloid was made on clinical grounds and biopsy.
A thorough history with regard to the onset of the lesion and whether it 
was spontaneous or followed acne, folliculitis, insect bite, varicella, 
trauma, surgery was taken to assess the etiology of the disease. The 
duration, progression of lesion, associated symptoms, family history were 
also asked for. The patients were also enquired about past history of 
thyroid disease and drug intake (retinoids, anabolic steroids) prior to the 
onset of the lesions.
A meticulous general and systemic examination was performed to look 
for associations. Complete dermatological examination was carried out. 
The site, number, size, consistency, colour of the lesions were noted. Care 
was taken to look for associated skin lesions.
A complete hemogram, liver function tests, renal function tests, blood 
group was done in all the cases. ECG and ECHO were done and 
cardiology opinion was obtained in patients who were to be started on 
injection Verapamil.
30
30
INCLUSION CRITERIA:
1. Age group 10- 60 years.
2. Both sexes.
3. Size of keloid between 1- 15 cm
4. Duration of less than 15 years.
EXCLUSION CRITERIA:
1. Pregnancy
2. Lactation
3. Heart disease.
4. Liver and kidney disease
5. Immunocompromised patients
6. H/O previous treatment
Patients were allocated to each group by simple randomisation. Clinical 
assessment of the scars was performed at the beginning of the study, and 
at every three weeks interval after starting treatment. The drugs were 
administered till the scars flattened or for a maximum period of 18 weeks 
whichever was earlier.
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GROUP 1: Patients submitted for Intralesional Triamcinolone 
acetonide (40mg/ml):
Fifteen patients comprising the first group were treated with injection 
Triamcinolone acetonide 40mg/ml, with a 27 gauge needle attached to an 
insulin syringe. 0.2 ml was injected in each site (1cm2), so as to cause 
blanching. The injection was given segment wise sequentially by multiple 
puncture technique so as to cover the entire lesion. Care was taken not to 
cause blanching of the surrounding area. Pressure hemostasis was 
obtained and antibiotic dressing was done. The patients were given
injections at 3 weeks interval, till the flattening of the scar or for a 
maximum period of 18 weeks.
GROUP 2: Patients submitted for Intralesional 5- Fluorouracil 
injection (50mg/ml):
Fifteen patients comprising the second group were treated with injection
5- Fluorouracil 50mg/ml with a 27 gauge needle attached to an insulin 
syringe. 0.2ml was given at each site (1cm2), sequentially by multiple 
puncture technique so as to cover the entire lesion. The injections were 
given at intervals of 2 weeks till the flattening of the scar or a maximum 
period of 18 weeks.
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GROUP 3: Patients submitted for Intralesional Verapamil (2.5mg/ml)
injection:
Fifteen patients comprising the third group were treated with injection 
Verapamil 2.5mg/ml with a 27 gauge needle attached to an insulin 
syringe. 0.2ml was injected at each site (1cm2), sequentially, and the 
entire lesion was covered. The injections were given every 3 weeks till the 
resolution of the lesions or a maximum duration of 18 weeks.
GROUP 4: Patients submitted for combination of injection                  
5 –Flourouracil (50mg/ml) and injection Triamcinolone (40mg/ml):
Fifteen patients comprising the fourth group were treated with
intralesional injection of 0.9ml of 5- Fluorouracil (50mg/ml) combined 
with 0.1ml of injection Triamcinolone (40mg/ml). 0.2ml of the 
combination was injected in each site (1cm2) sequentially with multiple 
puncture technique. The injections were given at intervals of 3 weeks till 
the lesions flatten or for a maximum of 18 weeks.
GROUP 5: Patients submitted for Cryotherapy followed by 
Intralesional Triamcinolone (40 mg/ml) combined with Silicone gel 
sheet application:
Fifteen patients comprising the fifth group were initially treated with 
Cryotherapy using liquid nitrogen applied by a cotton tipped wooden stick 
for a period of 20 to 30 seconds. A single freeze thaw cycle was applied. 
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This was followed by injection of 0.2 ml of Triamcinolone 
acetonide(40mg/ml) at each site (1cm2) sequentially to cover the entire 
lesion. Silicone gel sheets were applied over the lesions and kept in place 
by a micropore tape. The patient was advised to keep the sheet in place for 
8 hours per day. The injections were given at 3 weeks interval till the scar 
flattens or a maximum period of 18 weeks.
The clinical assessment of the scar was done based on Vancouver 101scar 
scale which was modified as scar vascularity could not be assessed due to 
lack of resources. The other parameters of the scar scale like 
pigmentation, pliability, height were assessed every three weeks.
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             PIGMENTATION:
0     -     Normal
1     -     Hypopigmentation
2     -      Mixed
3     -      Hyperpigmentation
PLIABILITY:
0     -      Normal
1     -       Supple (flexible with minimal resistance)
2     -       Yielding (giving way to pressure)
3     -       Firm (inflexible, resistant to manual pressure)
4     -       Banding (rope like tissue that blanches)
5     -       Contracture (permanent shortening of scar producing 
deformity)
HEIGHT:
0    -        Normal
1    -         < 2mm
2    -         2 to 5 mm
3    -          > 5mm
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Itching which is an important symptom in keloid was also assessed. The 
scale for self assessment of itching is as follows:
0    -   No itchy sensation
1    -   Sometimes itchy
2    -   moderately itchy , tolerable.
3    -   Severe intolerable constant itching
The complications of therapy like
a) Atrophy
b) Hypopigmentation
c) Hyperpigmentation
d) Depigmentation
e) Telangiectasia
f) Necrosis
g) Ulceration
h) Blistering
i) Pain and burning sensation were noted in each visit.
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STATISTICAL ANALYSIS:
The sample size for this study was calculated to be 15 in each group. For 
each study parameter, in each group, the mean value was calculated. Non 
parametric repeated measures ANOVA test (Friedman test) was used for 
analysis. Kaplan Meier graphs and log rank test were done to compare 
the rate at which all the study parameters reduced to zero with the 5 
modalities. Score 0 in each parameter was considered to be the complete 
response. To look for any significant association between the duration, 
size, etiology and number of lesions with treatment response (complete 
flattening), Fischer’s exact test was used. A p value of less than 0.05 was 
considered to be statistically significant.
OBSERVATIONS:
An analysis of the clinical profile of the patients recruited for the study 
revealed the following data.
There were 38 males and 37 females in our study group.
The ages of the patients ranged between 10 to 60 years .The majority of 
the males were in the 20 to 30 years age group, and the females were 
most common in the 30 to 40 years age group
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                                    TABLE 1: AGE AND SEX DISTRIBUTION:
AGE GROUP / SEX MALES FEMALES TOTAL
10-20 YEARS 4 10 14
21-30 YEARS 16 10 26
31- 40 YEARS 13 14 27
41-50 YEARS 1 2 3
51-60 YEARS 4 1 5
TOTAL 38 37 75
                                                   TABLE 2: ETIOLOGY OF KELOID:
ETIOLOGY NUMBER
SPONTANEOUS 51
TRAUMA 11
ACNE VULGARIS 7
HERPES ZOSTER 3
SURGERY 2
TATOO 1
51 patients had spontaneous onset of keloids. A history of trauma prior to 
the onset of the lesions was obtained in 11 patients. 7 patients had acne as 
the preceding lesion.3 patients had keloids occurring at the site of herpes 
zoster scar. 2 of them had keloids developing at the site of previous 
surgical scar. Keloid occurred at the site of tattoo in a single patient.
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The duration of the lesions ranged between 1 to 10 years in our study 
group. 20 patients had lesions of ≤ 1 year duration. Majority (37) had 
lesions of 2 to 4 years duration.18 patients had keloids ≥ 5 years 
duration.
A positive family history (8%) was obtained in 4 males and 2 females.
The number of keloids in each patient was also variable. 39 of them had a 
single lesion and 36 of them had multiple lesions. The number of keloids 
ranged between 1 to 22.
The size of the keloids was also assessed. The smallest was found to be 1
cm and the largest was found to be 13 cm. 43 patients had keloids of less 
than 5 cm and 32 of them had keloids more than 5 cm.
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                                             TABLE 3: SITES OF INVOLVEMENT:
SITES OF INVOLVEMENT NUMBER
CHEST 38
SHOULDER 16
FOREARM 10
ARM 3
BACK 2
ABDOMEN 2
THIGH 1
NECK 1
HAND 1
LEG 1
The sites of involvement in the descending order of frequency was found 
to be chest (38), shoulder (16) , forearm (10) , arm (3) , back (2), 
abdomen (2), thigh (1),neck (1), hand (1), leg(1).
Blood group 0+ve was found to be the commonest in our patients.
Diseases associated were Acne vulgaris, Pitryiasis versicolor and 
hirsuitism.
40
40
The distribution of keloids in each group according to the etiology, 
duration, number, size, and sites were found to be the following.
                                   TABLE 4: ETIOLOGY OF SCARS IN EACH GROUP:
ETIOLOGY/GROUPS GROUP
      1
GROUP
      2
GROUP
     3
GROUP
     4
GROUP
     5
SPONTANEOUS 10 11 12 11 7
ACNE 2 - 2 - 3
TRAUMA 2 4 1 1 3
SURGERY 1 - - 1 -
HERPES ZOSTER - - - 2 1
TATOO - - - - 1
This table depicts the cause of keloid in each group. This shows that the 
majority were spontaneous in onset in each group.
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                    TABLE 5: DURATION OF KELOID IN EACH GROUP:
DURATION 
IN YEARS
GROUP 1 GROUP 2 GROUP 3 GROUP 4 GROUP 5
≤ 1 YEAR 4 1 3 4 6
2- 4YEARS 8 9 10 5 7
≥ 5 YEARS 3 5 2 6 2
           
                      TABLE 6: NUMBER OF KELOIDS IN EACH GROUP:
NUMBER OF 
KELOIDS
GROUP 1 GROUP 2 GROUP 3 GROUP 4 GROUP 5
SINGLE
8 9 8 6 8
MULTIPLE
7 6 7 9 7
                         TABLE 7: SIZE OF KELOIDS IN EACH GROUP:
SIZE IN
CM
GROUP 1 GROUP 2 GROUP 3 GROUP 4 GROUP 5
≤5CM 9 8 9 8 9
>5CM 6 7 6 7 6
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                                TABLE 8: SITES OF KELOID IN EACH GROUP:
SITE GROUP 1 GROUP 2 GROUP 3 GROUP 4 GROUP 5
CHEST 9 6 6 8 9
THIGH - - - - 1
SHOULDER 2 3 6 3 2
FOREARM 3 2 1 2 2
ARM - 2 1 - -
BACK 1 - 1 - -
ABDOMEN - - - 1 1
NECK - 1 - - -
HAND - 1 - - -
LEG - - - 1 -
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OBSERVATIONS OF THERAPEUTIC 
RESPONSES:
GROUP 1: RESULTS OBTAINED IN PATIENTS TREATED 
WITH INTRALESIONAL TRIAMCINOLONE (40 MG/ ML) 
INJECTION:
Note: The mean values of each parameter are depicted in this table, and 
the p values are shown in the bracket.
PARAMETER/ 
NO OF WEEKS 0 3 6 9 12 15 18
PIGMENTATION 2.73 2.33
(>0.05)
1.73
(<0.001)
1.46
(<0.001)
1.26
(<0.001)
1
(<0.001)
0.93
(<0.001)
PLIABILITY 3 2.26
(>0.05)
1.67
(<0.01)
1.2
(<0.01)
0.73
(<0.001)
0.6
(<0.001)
0.4
(<0.001)
HEIGHT 2.46 2.2
(>0.05)
1.73
(>0.05)
1
(<0.001)
0.6
(<0.001)
0.4
(<0.001)
0.26
(<0.001)
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NUMBER OF    
WEEKS/ 
PARAMETERS
PIGMENTATION PLIABILITY HEIGHT
3 - 6.67% -
6 6.67% 6.67% 6.67%
9 6.67% 40% 26.67%
12 6.67% 53.33% 53.33%
15 13.34% 66.67% 66.67%
18 13.34% 73.33% 73.33%
This table shows the percentage of subjects who showed complete 
response at different weeks for each parameter studied.
There was a significant reduction in pigmentation (p value <0.001) by 6th 
week. 13.34% of subjects showed complete response by 18th week.
Pliability showed significant reduction by 6th week (p value <0.01).
73.33% of subjects showed complete response by 18th week. The median 
response time was found to be 12 weeks.
Significant reduction in height was seen by the 9th week (p<0.001). 
73.33% of the patients showed complete response by 18th week. The 
median response time was 12 weeks. There was a significant reduction in 
itch (p <0.001) by the 3rd week in this group.
The common side effects observed were hypopigmentation (14), atrophy 
(5), telangiectasia (5), pain (15).
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GROUP 2: RESULTS OBTAINED IN PATIENTS TREATED 
WITH INTRALESIONAL 5 – FLOUROURACIL (50MG/ML):
Note: The mean values of each parameter are shown in the table, and the p 
values are depicted in the bracket.
NUMBER OF 
WEEKS/ 
PARAMETER
PIGMENTATION PLIABILITY HEIGHT
12 - 6.67% 7%
15 - 20% 20%
18 - 26.67% 26.67%
This table shows the percentage of subjects who showed complete 
response at different weeks for each parameter studied.
PARAMETER/         
NO OF   WEEKS 0 3 6 9 12 15 18
PIGMENTATION 2.86 2.86
(>0.05)
2.6
(>0.05)
2.4
(<0.05)
2.2
(<0.001)
2.06
(<0.001)
2.06
(<0.001)
PLIABILITY 3 3
(>0.05)
2.33
(<0.05)
2
(<0.001)
1.8
(<0.001)
1.53
(<0.001)
1.4
(<0.001)
HEIGHT 2.4 2.4
(>0.05)
2.4
(>0.05)
2.13
(>0.05)
1.93
(>0.05)
1.4
(<0.01)
1.06
(<0.001)
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There was a significant reduction in pigmentation by 9 weeks.                 
(p value <0.05). None of the patients showed complete response by 18th
week.
A significant reduction in pliability was noted by 6 weeks (p value <0.05). 
Only 26.67% of the subjects showed complete response by 18 weeks.
Height showed significant reduction by 15 weeks (p value<0.01).Only 
26.67% of the patients showed complete response by 18 weeks.
There was a significant reduction in itch (p <0.001) by the 15th week in 
this group.
Hyper pigmentation and pain were the most common side effects
observed. It was seen in 14 patients. Burning sensation immediately after 
injection was seen in all the patients. The other commonly seen side 
effects were blistering of the lesions (10), necrosis (1), ulceration (3).
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GROUP 3: RESULTS OBTAINED IN PATIENTS TREATED 
WITH INTRALESIONAL VERAPAMIL (2.5MG/ML):
PARAMETER/ 
NO OF WEEKS
0 3 6 9 12 15 18
PIGMENTATION 3 2.93
(>0.05)
2.46
(<0.05)
2.13
(<0.001)
1.86
(<0.001)
1.8
(<0.001)
1.6
(<0.001)
PLIABILITY 3 2.53
(>0.05)
2.06
(<0.001)
1.8
(<0.001)
1.33
(<0.001)
0.86
(<0.001)
0.33
(<0.001)
HEIGHT 2.26 2.26
(>0.05)
2.06
(>0.05)
1.73
(>0.05)
1.13
(<0.001)
0.86
(<0.001)
0.53
(<0.001)
Note: The mean values of each parameter are shown in the table and the p 
values are noted in the brackets.
This table shows the percentage of patients who showed complete 
response at different weeks for each parameter studied.
NO OF WEEKS/ PARAMETER PIGMENTATION PLIABILITY HEIGHT
12 - 6.67% 6.67%
15 6.67% 26.67% 26.67%
18 6.67% 53.34% 53.34%
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There was a significant reduction in pigmentation by 6th week ( p value 
<0.05) 6.67% of the subjects showed complete response by 18th week.
Significant reduction in pliability was noted by 6th week (p value <0.001). 
53.34% of the patients showed complete response by 18 weeks. The 
median response time was found to be 18 weeks.
Height showed significant decrease by 12th week(p<0.001). 53.34% of the 
patients showed complete response by 18th week. The median response 
tine was found to be 18 weeks.
There was a significant reduction (p< 0.001) in itch by the 3rd week.
Pain was the only untoward effect observed in this modality of treatment. 
It was seen in 8 patients.
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GROUP 4: RESULTS OBTAINED FROM  PATIENTS TREATED 
WITH A COMBINATION OF 0.9ML OF INJECTION
5-FLOUROURACIL (50MG/ML) AND 0.1ML OF INJECTION 
TRIAMCINOLONE ACETONIDE (40MG/ML):
Note: The mean values of each parameter are shown in the table and the p 
values are depicted in the bracket.
PARAMETERS/ 
NO OF WEEKS
0 3 6 9 12 15 18
PIGMENTATION 2.93 2.6
(>0.05)
2.13
(<0.01)
1.73
(<0.001)
1.46
(<0.001)
1.13
(<0.001)
1.13
(<0.001)
PLIABILITY 3 2.46
(<0.05)
1.93
(<0.01)
1.35
(<0.001)
0.66
(<0.001)
0.4
(<0.001)
0.4
(<0.001)
HEIGHT 2.4 2.4
(>0.05)
2.06
(<0.05)
1.46
(<0.05)
0.66
(<0.001)
0.6
(<0.001)
0.4
(<0.001)
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NO OF WEEKS/ 
PARAMETERS
PIGMENTATION PLIABILITY HEIGHT
9 - 7% 7%
12 6.67% 60% 60%
15 13.34% 66.67% 66.67%
18 13.34% 66.67% 66.67%
This table shows the percentage of patients who showed complete 
response at different weeks for each parameter studied.
There was a significant reduction in pigmentation by the 6th week            
(p value <0.01). 13.34% of the patients showed complete response by 18 
weeks.
Pliability showed significant reduction by the 3rd week (p value <0.05). 
66.67% of the patients showed complete response by 18 weeks. The 
median response time was found to be 12 weeks.
Significant reduction in height was seen by the 6th week (p value < 0.05). 
66.67% of the patients showed complete response by 18 weeks. The 
median response time was calculated to be 12 weeks. There was 
significant reduction in itch (p <0.001) by the 3rd week.
The side effects were atrophy in 2 patients, hypopigmentation and pain in 
14 patients. Telangiectasia was seen only in one patient.
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GROUP 5: RESULTS OBTAINED WITH PATIENTS TREATED 
WITH A COMBINATION OF CRYOTHERAPY, 
INTRALESIONAL TRIAMCINOLONE ACETONIDE (40MG/ML) 
AND SILICONE GEL SHEETS:
PARAMETERS/ 
NO OF WEEKS
0 3 6 9 12 15 18
PIGMENTATION 3 2.46
(<0.05)
2.06
(<0.001)
1.6
(<0.001)
1.26
(<0.001)
1.13
(<0.001)
1
(<0.001)
PLIABILITY 3 2.26
(<0.01)
1.8
(<0.001)
1
(<0.001)
0.33
(<0.001)
0.2
(<0.001)
0.2
(<0.001)
HEIGHT 2.46 2
(>0.05)
1.6
(<0.001)
0.73
(<0.001)
0.46
(<0.001)
0.266
(<0.001)
0.2
(<0.001)
Note: The mean values of each parameter are shown in this table and the p 
values are shown in the bracket.
This table shows the percentage of subjects who showed complete 
response at different weeks for each parameter studied.
NO OF WEEKS/ 
PARAMETERS
PIGMENTATION PLIABILITY HEIGHT
9 - 26.67% 33.33%
12 - 73.33% 60%
15 6.67% 80% 80%
18 20% 80% 80%
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There was a significant reduction in pigmentation by the 3rd week (p value 
<0.05). 20% of the patients showed complete response by18 weeks.
Significant reduction in pliability was noted by the 3rdweek (p value 
<0.01). 80% of the subjects showed complete response by 18 weeks. The 
median response time was found to be 12 weeks.
Height showed significant reduction by 6 weeks (p value <0.001).80% of 
the subjects showed complete response by 18 weeks. The median 
response time was found to be 12 weeks. There was a significant 
reduction in itch (p< 0.001) by the 3rd week.
Hypopigmentation and pain were seen in 14 patients, atrophy in 4 patients
and telangiectasia in 3 patients.
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PERCENTAGE OF PATIENTS WITH COMPLETE RESPONSE AT THE END OF THE 
STUDY PERIOD:
This table shows the percentage of patients with complete response with 
respect to each parameter at the end of 18 weeks.
PARAMETER/ 
GROUPS
PIGMENTATION PLIABILITY HEIGHT
GROUP 1 13.34% 73.33% 73.33%
GROUP 2 - 26.67% 26.67%
GROUP 3 6.67% 53.34% 53.34%
GROUP 4 13.34% 66.67% 66.67%
GROUP 5 20% 80% 80%
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DISCUSSION:
GROUP 1: PATIENTS TREATED WITH INTRALESIONAL 
TRIAMCINOLONE ACETONIDE (40 MG/ML):
The therapeutic response in each parameter has been assessed. The study 
done by Margaret Shanthi et al76 showed a significant reduction in 
pigmentation by the 3rdweek. There was a significant change in 
pigmentation by the 6th week and 13.34% (2) of the patients showed 
complete response by 18 weeks in our study.
The study conducted by Manuskiatti 91et al showed a significant change in 
pliability by 8 weeks and the study by Margaret Shanthi 76et al had shown 
a significant change in pliability as early as 3 weeks. There was a 
significant change in pliability by 6th week in our study. The median 
response time was found to be 6 weeks in the study conducted by 
Margaret Shanthi 76et al when compared to our study where it was found 
to be 12 weeks. 73.33% (11) of the patients had shown complete response 
by 18 weeks in our study.
The study conducted by Darougheh A 92et al has shown that only 20% of 
the patients showed complete flattening by 12 weeks. Another study 
conducted by Muneuchi G 68et al shows complete response in 40% of the 
patients. Layton AM and Yip J63 et al had shown complete response in 
85% of the patients, in concordance with our study.73.33% (11) of the 
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patients had shown complete flattening by 18 weeks in our study. The 
study conducted by Manuskiatti 91et al showed significant flattening by 
the 8th week, which is in concordance with our study where significant 
flattening was achieved by the 9th week. The median response time in the 
study conducted by Margaret Shanthi et al76 was found to be 6 weeks, 
when compared to our study where it was 12 weeks. The variation of the 
results in our study may be attributed to the fact that patients with family 
history of keloids, keloids of more than 5 years duration, size more than 
10 cm were not included in the study conducted by Margaret Shanthi76 et 
al. And it has been shown by previous studies that keloids of longer 
duration had delayed response to treatment.
Adverse effects like hypopigmentation were noted in 14 patients 
(93.33%). This is significantly higher than that seen in the study 
conducted by Manuskiatti 91et al where it was 20%. The other untoward 
effects seen were atrophy (33.33%), telangiectasia (33.33%). Manuskiatti 
91et al had recorded atrophy and telangiectasia in 20% of his patients 
treated with Triamcinolone acetonide. Pain was noted in all the patients, 
similar to the study conducted by Manuskiatti91 et al. Of the 15 patients in 
this group , 4 patients (26.67%) did not show complete flattening at the 
end of 18 weeks. 3 of the four patients had keloids of more than 1 year
duration. Of all the other patients who showed complete response at 18 
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weeks, 2 had keloids of less than or equal to 1 year duration and 9 had 
keloids of more than 1 year duration.
3 out of 4 patients who did not show complete flattening at 18 weeks, had 
keloids of more than 5 cm size. But 3 patients with keloid of more than 5 
cm size had shown complete response by 18 weeks.
5 out of 11 patients who had shown complete flattening had only a single 
keloid. The remaining 6 of them had multiple keloids. Among those who 
did not achieve complete flattening 2 had single keloid and 2 had multiple 
keloids.
Of the four patients who did not show complete flattening, 2 had 
spontaneous onset of keloids, and 1 patient had acne as the preceding 
lesion and the other had trauma preceding the onset of lesions. Of the 
subjects who showed complete flattening 8 had spontaneous of keloids, 1 
had acne as the preceding lesion. Surgery and trauma preceded the onset 
of lesions in 1 patient each.
The site of involvement in 3 out of the 4 patients was the chest. Forearm 
was the site involved in the other patient. The patients who had shown 
complete response had sites of distribution as follows. Chest in 6, forearm 
in 2, shoulder in 2, upper back in 1 patient respectively.
57
57
GROUP 2: PATIENTS TREATED WITH INTRALESIONAL          
5-FLOUROURACIL (50MG/ML):
In this study group none of them showed complete response with regard
to pigmentation. A significant change in pigmentation was observed by 
the 9th week. None of the patients showed complete response by the end 
of 18 weeks also.
The study done by Manuskiatti91 et al showed a significant reduction in 
pliability by 16 weeks when compared to our study where it was found to 
be 6 weeks. 4 out of 15 patients (26.67%) showed complete response in 
our study.
Manuskiatti et al91 had shown a significant reduction in height by 8 weeks 
when compared to our study where it was achieved by 15 weeks. This 
may be due to the fact that weekly injections were given in the study in 
contrast to our study where the patients were treated with injections at 2 
weeks interval. The study of Wu XL93 et al showed complete flattening in 
45.71% of the patients, when compared to our study where 26.67% (4 out 
of 15) of the patients showed complete response. This may be due to the 
fact that in that study biweekly injections of the drug were given. In our 
study, a time interval of 2 weeks between the injections was chosen as the 
incidence of side effects was found to be significantly higher, when the 
injections are given frequently, as observed in the earlier studies.
58
58
The occurrence of side effects was found to be severe in this treatment
modality compared to the others. The study conducted by 
Kontochristopoulos74 et al has shown that hyperpigmentation and pain 
after injection were seen in 100% of the patients. Hyperpigmentation in 
14 patients (93.33%) and pain   immediately after injection in 14 patients 
(93.33%) were observed in our study.
The study conducted by Manuskiatti91 et al indicates burning sensation as 
an important adverse effect seen in all the patients. All the patients in our 
study complained of burning discomfort immediately after instillation of 
the drug. Blistering was seen in 10 patients (66.67%) in our study. The 
blisters appeared within 6 hours to 24 hours after the injection and burst 
spontaneously. It has also been observed that the incidence of blisters was
more in the first two injections, and it decreased in subsequent injections. 
In the study of Fitzpatrick72 et al ulceration was seen in 30% of the 
patients when compared to our study where it was observed in 20% of the 
patients (3). This could be attributed to the less frequent dosage in our 
study.
11 out of 15 patients (73.33%) did not show complete flattening of the 
lesion by 18 weeks. All the patients who had not shown complete 
flattening had keloids of more than 1 year duration. Among the 4 patients 
who showed complete flattening by 18 weeks, 3 of them had keloids of 
more than 1 year duration and 1 had keloid of ≤ 1 year duration.
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5 of the 11 patients who did not achieve complete flattening had keloids 
less than or equal to 5cm and 6 of them had keloids of more than 5 cm.3 
out of 4 patients who had complete flattening , had keloids ≤ 5cm and one 
patient had keloid >5cm.
In this group, all the 4 patients who had shown complete flattening had a 
single keloid. Out of the 11 patients who did not have complete flattening 
by the end of 18 weeks, 5 of them had a single keloid and the remaining 6 
had multiple keloids.
The predisposing factors in these 11 patients were found to be trauma in 
2, and spontaneous onset in the remaining 9 patients. Among the subjects 
who showed complete flattening by the end of 18 weeks, 2 had 
spontaneous onset and 2 of them had prior history of trauma.
The sites of involvement in these 11 patients were chest (3), shoulder (3), 
arm(2), forearm(1), hand(1), neck(1). Among the 4 patients who 
responded completely, 3 had lesions in the chest and 1 patient had lesion 
over the forearm.
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GROUP 3: PATIENTS TREATED WITH INTRALESIONAL 
VERAPAMIL (2.5MG/ML):
The study conducted by Margaret Shanthi, Kalpana Ernest and Prema
dhanraj76 et al showed a significant reduction in pigmentation by the 9th 
week when compared to our study where it was achieved by 6 weeks.
6.67% (1) of the patients showed complete response with regard to 
pigmentation, in our study.
In the study of Margaret Shanthi76 et al a significant change in pliability 
was seen in 3 weeks, when compared to our study where it was achieved 
by 6 weeks. 8 out of 15 patients (53.34%) showed a complete response by 
the end of 18 weeks in our study with respect to pliability. The study done 
by Margaret Shanthi 76et al showed the median response time to be 9 
weeks when compared to our study where it was recorded to be 18 weeks.
In the study conducted by Margaret Shanthi76 et al a significant change in 
height was observed by 3 weeks when compared to our study where it was 
seen by 12 weeks. In the study conducted by Margaret Shanthi76 et al the 
median response time was found to be 9 weeks, in contrast to our study 
where it was found to be 18 weeks. 8 patients (53.34%) showed complete 
flattening of the lesions by the end of 18 weeks in our study.
The variation of the results from the study of Margaret Shanthi 76et al may 
be due to the following reasons. The exclusion criteria in their study were
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patients with family history of keloids, darkly pigmented skin. The 
inclusion criteria in their study was patients with keloids of 2 to 10cm 
size, duration of less than 5 years, and cause of scar being trauma, 
surgery, insect bite , acne. In our study patients with family history, 
keloids of duration upto 15 years, size upto 15cm were included. Patients 
with spontaneous keloids were also included in our study. As it has been 
proved by earlier studies that keloids of longer duration are resistant to 
treatment, this might have had an influence in the treatment, in our study 
also.
On reviewing the side effects in the patients of this group, it was noted 
that pain was the only side effect noted. It was seen in 8 patients 
(53.33%). This is significantly lower when compared to the other 
treatment modalities. No other untoward effects were noted. This is in 
concordance to the study of Margaret Shanthi76 et al.
46.66% (7) of the patients did not show complete flattening by the end of 
18 weeks. Out of which 6 had keloids more than one year duration and 1 
patient had keloid of ≤ 1 year duration. 2 of the 8 patients who had shown 
complete flattening by the end of 18 weeks, had keloids of ≤ 1 year
duration, and the remaining 6 had keloids of more than a year duration.
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4 out of the 7 patients who had not achieved complete flattening had 
keloids of size ≤ 5 cm and 3 had keloids of >5cm size. Among the patients 
who responded completely, 3 had size >5cm and 5 had size ≤ 5cm.
Of the 8 patients who had complete flattening by the end of 18 weeks, 6 
had only a single keloid and 2 had multiple keloids. 5 patients who had 
multiple keloids and 2 of them who had a single keloid, did not achieve 
complete flattening by the end of 18 weeks.
5 of the 7 had spontaneous onset of keloids and history of acne preceding 
the onset of keloid was obtained in two patients. Of the 8 patients who had 
shown complete flattening by 18 weeks, 7 had spontaneous onset, 1 
patient had prior history of trauma.
Arm(1) shoulder (2)and chest(3), back(1) were the sites of involvement in 
the 7 patients, who had not achieved complete flattening. The patients 
who showed complete flattening by 18 weeks had the following sites of 
involvement.  Shoulder (4), Chest (3), forearm(1).
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GROUP 4: PATENTS TREATED WITH A COMBINATION OF 
0.9ML OF INTRALESIONAL 5 – FLOUROURACIL (50MG/ML) 
AND 0.1ML OF INTRALESIONAL TRIAMCINOLONE
(40MG/ML):
2 patients showed complete response in terms of pigmentation by the end 
of the study period. A significant change in pigmentation was noted by the 
6th week. 13.34% of the patients showed complete response by 18 weeks.
The study conducted by Manuskiatti 91et al has shown a significant 
change in pliability by 8 weeks when compared to our study where it was 
seen by 3 weeks. This may be due to the fact that a lower concentration of 
Triamcinolone (20mg/ml) was used by them and the time interval 
between the doses was increased to 4 weeks in the last two treatments.
66.67% (10) of the patients showed complete response by 18 weeks and
the median response time was found to be 12 weeks in our study.
The study of Asilian, Darougheh92 et al showed complete response in 55% 
of the patients when compared to our study where 66.67% (10) of the 
patients had achieved complete flattening. The study by Manuskiatti 91et 
al showed a significant change in height by 8 weeks when compared to 
our study where it was seen by 6 weeks. This may be due to the lower 
concentration of Triamcinolone used in their study and also the less 
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frequent dosing of once in 4 weeks for the last two treatments. The 
median response time was found to be 12 weeks in our study.
Regarding the side effects observed in this group, hypopigmentation and 
pain was noted in 14 patients (93.33%). Atrophy was seen in 2 patients 
(13.33%) and telangiectasia in 1 patient (6.67%). This is lower when 
compared to that observed in the patients treated with Triamcinolone 
alone.
33.33% of the patients did not show complete flattening by the end of 18 
weeks. All the patients who had not shown complete flattening by 18 
weeks had keloids of more than 1 year duration. 4 patients with duration 
of less than or equal to 1 year and 6 patients with keloid of more than 1 
year duration showed complete flattening  by the end of 18 weeks.
Considering the onset of keloids in these 5 patients, 4 had spontaneous 
onset and 1 patient had keloid developing at the site of previous surgical 
scar. 7 patients with spontaneous onset of keloids, 2 patients with keloids 
occurring at the involvement of herpes zoster lesions, 1 patient with a 
history of trauma prior to the onset of keloid showed complete flattening 
by the end of 18 weeks.
4 patients with keloid of size more than 5 cm size and one patient with 
keloid of less than 5 cm size did not show complete flattening by the end 
of 18 weeks. It was observed that 7 of the 10 patients who showed 
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complete flattening had keloids of less than 5 cm size and 3 of them had 
keloids of more than 5 cm size.
Out of the 10 patients who had shown complete flattening by 18 weeks, 5 
had a single keloid and the remaining 5 had multiple keloids. 1 patient 
with single keloid did not show complete flattening by 18 weeks.4 of the 
remaining patients who had not shown complete flattening had multiple 
keloids.
4 patients who did not show complete flattening had keloid in the chest, 
and one had keloid over the shoulder. The sites of involvement in the 
subjects who showed complete flattening were as follows. Chest (4), 
shoulder (2), forearm(2), abdomen(1), leg(1).
GROUP 5: PATIENTS TREATED WITH CRYOTHERAPY, 
INTRALESIONAL TRIAMCINOLONE AND SILICONE GEL 
SHEETS:
Complete response with respect to pigmentation was seen in 3 patients. A 
significant change in pigmentation was seen in 3 weeks. 20% of the 
patients showed complete response by 18 weeks.
Complete response in terms of pliability was seen in 12 patients. A 
significant change in pliability was noted as early as 3 weeks. 80% of the 
patients showed complete response as early as 15 weeks. The median 
response time was found to be 12 weeks.
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80% of the patients showed complete flattening of the lesion by 15 weeks. 
A significant change in height was noted by the 6th week. The median 
response time was found to be 12 weeks.
The side effects observed were hypopigmentation in 14 patients (93.33%),
Atrophy in 4 patients (26.67%), and telangiectasia in 3 patients (20%), 
pain in 14 patients.
In this group, 80% of the patients had shown complete response by 15 
weeks. All the patients who had not shown complete flattening at 18 
weeks had keloids of more than 1 year duration. Among the patients who 
had shown complete flattening at 18 weeks, 6 patients had keloids ≤ 1year
and 6 patients had keloids of more than 1 year duration. All the three 
patients who had not shown complete flattening had keloids of size more 
than 5cm. Among the subjects who had shown complete flattening 9 of 
them had keloids of less than 5cm and 3 of them had keloids of size more 
than 5cm.
Out of the 12 patients who had shown complete flattening, 5 had only a 
single keloid and 7 had multiple keloids. Of the 3 patients who had not 
achieved complete flattening by the end of the study period, 2 had a single 
keloid and one person had multiple keloids.
Considering the etiology of keloids, 2 of the three patients had 
spontaneous onset of keloids and the other patient had keloid occurring at 
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the site of tattoo. Among the patients who had shown complete flattening,
5 of them had spontaneous onset of keloids, 3 of them had acne, 3 of them 
had trauma as the preceding event. One patient had keloid occurring at the 
site of previous herpes zoster lesion.
2 of the three patients who had not attained complete flattening by 18 
weeks, had keloids in the chest and one patient had lesions over the 
forearm. 7 of the 12 patients who had shown complete flattening had 
lesions over the chest, 2 in the shoulder, and one each in the forearm,
abdomen and thigh.
To sum up, comparison of the different parameters like pigmentation, 
pliability, height in the various treatment modalities shows that complete 
response in pigmentation was obtained in 20% of the patients in group 5,
13.34% of patients in group 4, 13.34% of patients in group 1and 6.67% of 
patients in group 3 by the end 18 weeks. None of the patients showed 
complete response in terms of pigmentation in group 2.
With regard to pliability 80% of the patients in group 5 had shown 
complete response by 15 weeks.  73.33% of the patients in group 1, 
66.67% of the patients in group 4, 53.34% of the patients in group 3 and 
26.67% of the patients in group 2 had shown complete response by 18 
weeks.
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With regard to height, 80%of the patients in group 5 had shown complete 
response by 15 weeks. 73.33% of the patients in group 1, 66.67% in group 
4, 53.34% in group 3 and 26.67% in group 2 had shown complete 
response by 18 weeks.
There was a statistically significant reduction in itch by 3 weeks in all the 
groups except group 2 where there was a significant reduction only by 15 
weeks.
The side effects were found to be severe in the group treated with 5-
fluorouracil alone and were least in the group treated with Verapamil.
In the first group on comparing the treatment response in patients with 
keloids ≤ 1year with keloids of more than a year duration there is no 
statistically significant difference. (p=1.00).
In group 1 there is no statistically significant difference in the treatment 
response of keloids ≤ 5cm and keloids of more than 5 cm. (p=0.2352).
When the treatment response between single and multiple keloids are 
compared in the first group, no statistically significant difference is found. 
(p=1.00)
In group 1,when the treatment response between keloids of spontaneous 
onset and those due to other causes are compared , no statistically 
significant difference is found.(p=1.00)
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In group 2, on comparing the treatment response in patients with keloids ≤ 
1year and keloids of more than 1 year, no statistically significant 
difference is found. (p=0.2667).
In group 2, there is no statistically significant difference between keloids 
of size ≤5cm and keloids of more than 5cm (p=0.5692), regarding the 
treatment response.
When the treatment response between single and multiple keloids are 
assessed in group 2, no significant difference is found. (p=0.1033).
When the treatment response between keloids of spontaneous onset and 
those due to other causes are compared in this group, no statistically 
significant difference is found.(p=0.5165).
In group 3, when the treatment response is compared between keloids ≤1 
year and keloids of more than a year duration no statistically significant 
difference is found. (p=1.00).
In the third group, there is no statistically significant difference between 
the treatment response in keloids ≤ 5cm and keloids of more than 5 cm 
size (p=1.00).
When the treatment response in patients with single and multiple keloids 
are compared in group 3, no statistically significant difference is found. 
(p=0.1319).
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In group 3, when the treatment response between keloids of spontaneous 
onset and those due to other causes are compared, no statistically 
significant difference is found.(p=0.5692)
On assessing the treatment response in patients with keloids ≤1 year and 
keloids of more than a year duration in group 4, no significant difference 
is found (p= 0.2308).
In the fourth group, no statistically significant difference is found on 
comparing keloids of size ≤5cm and keloids of more than 5 cm size. 
(p=0.1189).
In the fourth group, no significant difference is found in the treatment 
response between single and multiple keloids. (p=0.5804).
In group 4, on comparing the treatment response in keloids of 
spontaneous onset and those due to other causes, no statistically 
significant difference is found. (p=1.00)
On comparing the treatment response in keloids ≤ 1year duration and 
keloids of more than a year duration in the fifth group, no statistically 
significant difference is found.(p=0.2286).
In the fifth group, no significant difference is noted in the treatment 
response between keloids ≤ 5cm and keloids of more than 5cm size. 
(p=0.2418).
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No significant difference is noted in the treatment response between 
single and multiple keloids in group 5 (p=0.5692).
On comparing the treatment response in keloids of spontaneous onset and 
those due to other causes in the fifth group, no statistically significant 
difference is found (p=0.5692).
The best and earlier response (15 weeks) is seen in the group treated with 
a combination of Cryotherapy, Intralesional Triamcinolone acetonide and 
Silicone gel sheets. It has been found by earlier studies106, that collagen 
breakdown by the steroid injection augments tissue polarization by the 
negatively charged static electric field on the silicone sheet. In a study by 
Eishi K et al84, it has been observed that silicone gel sheets decrease the 
number of mast cells and increase the expression of Fas Ag by the lesional 
fibroblasts. This along with the action of Triamcinolone could have led to 
the faster resolution of keloids in this study group.
The group treated with 5- Flourouracil alone had shown the least response 
among the 5 study groups. A study conducted by Haurani et al105 has 
shown that 5 – Flourouracil relies on thymidylate synthase activity to 
initiate apoptosis. And it has been shown that there is downregulation of 
apoptosis related genes in the keloid tissues108, so this may result in a 
relative resistance to the medication. A study conducted by 
Kontochristopoulous74 has shown that TGF – β expression is not 
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dramatically altered by 5 – Florouracil when compared to steroids. And 
the role of TGF – β in the pathogenesis of keloid is well known. All these 
factors could have led to the comparatively less response seen in this 
study group.
It has been observed that 73.33% of the patients treated with intralesional 
Triamcinolone acetonide alone and 66.67% of the patients treated with a 
combination of 5 – Flourouracil and Triamcinolone acetonide had shown 
complete flattening by 18 weeks. It has been observed that steroids 
increase b- FGF and decrease TGF- β107.They also decrease the levels of 
IL- 1,6 which are known to be involved in keloid pathogenesis31. The 
number of mast cells and the release of histamine by mast cells is also 
decreased by steroids. But these factors are not altered by the use of 5-
fluorouracil alone. This might have had an influence on the treatment 
response in our study as it is observed that the use of Triamcinolone alone 
or its combination with 5- Flourouracil produced better response 
compared to the use of 5 – fluorouracil alone.
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     CONCLUSION:
1. In our study the prevalence of keloids was found to be equal among 
both sexes.
2. The majority of keloids were seen in the 20 to 40 years age group in 
our study.
3. The maximum number (68%) of patients had spontaneous onset of 
keloids in our study. The other common risk factors observed were 
trauma, Acne vulgaris, herpes zoster, surgery, and tattoo in the 
descending order of frequency.
4. The most common site of occurrence of keloid in our study was 
observed to be the chest (50%). The other sites of involvement were 
shoulder, forearm, arm, back, abdomen, thigh, neck, hand and leg.
5. A positive family history was observed in 8% of the patients in our 
study.
6. The response to treatment varied between the study groups, for the 
three parameters assessed. The patients treated with a 
combination of Cryotherapy, Intralesional Triamcinolone 
acetonide and silicone gel sheets showed the best and the 
earliest response, among all the 5 study groups (Pigmentation –
20%, Pliability and Height – 80%).
7. 73.33% of the patients treated with Intralesional triamcinolone 
acetonide had shown complete response with respect to 
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pliability and height. 13.34% of the patients had shown 
complete response to pigmentation in this group.
8. Complete response was seen in 66.67% of the patients treated 
with a combination of Intralesional Triamcinolone Acetonide 
and 5 – Flourouracil with respect to pliability and height. 
13.34% of the patients showed complete response to 
pigmentation in this study group.
9. In the group treated with Intralesional Verapamil, 53.34% of 
the patients had shown complete response in pliability and 
height. 6.67% of the patients showed complete response to
pigmentation in this group.
10.The patients treated with Intralesional 5- Fluorouracil had 
shown the least response among all the 5 study groups.
(Pigmentation – 0%, Pliability and Height – 26.67%).
11.Itching was significantly reduced (p<0.001) in all the five 
modalities of treatment.
12.The side effects were severe in the group treated with                     
5- Fluorouracil alone and least in the group treated with Verapamil.
13.The number of keloids (single and multiple) in a patient does not 
significantly alter the treatment response in any of the study groups 
(p > 0.05).
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14.There is no significant association between the size of the keloids 
and the response to therapy in any of the study groups (p> 0.05).
15.No significant association is observed between the duration of 
keloids   (≤ 1year and > 1 year) and the treatment response
(p>0.05). Each group in our study is comprised of 15 patients only. 
This remains the limitation of our study. Therefore studies in larger 
groups are needed to identify the influence of such factors on the 
treatment response.
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                                                            PROFORMA                      
Name: Age: Sex:    IP No: Occupation:
Address:
Phone No:
Complaints:
H/O Present Illness: 
 Onset and duration of the lesion:
 H/O Pain:
 H/O Itching:
 H/O Burning Sensation:
 H/O Ulceration:
 H/O Discharge:
 H/O Trauma:
 H/O Sudden Increase In Size:
 H/O Vaccination:
 H/O Burns Or Scalds:
 H/O Varicella Infection:
 H/O Acne:
 H/O any other infected skin lesion:
 H/O Surgery:
 H/O Drug Intake:
Past H/O
 H/O Diabetes Mellitus, Hypertension, Thyroid Disease.
 H/O similar skin lesions elsewhere in the body in the past:
Family H/O
 H/O any other family members affected:
Personal H/O
 Diet:
 Alcoholism, Smoking:
Treatment H/O
H/O any treatment taken in the past:
General Examination
Built: Height:   Weight:               Pallor:        Icterus: 
Cyanosis:        Lymphadenopathy:                        Clubbing:        
Specific Features If Any:                        
Systemic Examination
CVS: RS:       Abdomen:
CNS: Joints:
Dermatological Examination
Inspection
Number:           Site:    Length:             Width:          Height:     
Discharge:
Palpation
Warmth:                   Tenderness:                 Consistency:
Other Skin Lesions (If Any):
Nails: Oral and Genital Mucosa: Palms and soles:
Investigations
Complete Hemogram:
  LFT:
  RFT:
  Fasting Lipid Profile:
  Blood Group:                 X ray Chest:                          ECG and cardiac
  status: 
                 
Treatment Modality Chosen (Specify the Modality Chosen)
Side Effects and Response
                                 No of Weeks
                       3   6 9 12 15 18
Atrophy:
Hyperpigmentation:
Hypopigmentation:
Telangiectasia:
Necrosis:
Ulceration:
Blistering:
Depigmentation:
Pain:
Assessment of Treatment Response:
                                                                      No of weeks
                                                                     0     3     6    9     12    15     18
                                      
 Height:
0 – Normal
1 – < 2mm
2 – 2 to 5mm
3 – >5mm
 Pigmentation:
0 – Normal
1 – Hypopigmentation
2 – Mixed
3 – Hyperpigmentation
 Pliability:
0 – Normal
1 – Supple
2 – Yielding
3 – Firm
4 – Banding
5 – Contracture
 Itching:
0 – No Itching
1 – Sometimes Itchy
2 – Moderate,tolerable itching
3 – Severe, intolerable itching
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     KEY TO MASTER CHART: 
1. P - Pigmentation 
2. PL – Pliability 
3. H – Height 
4. I – Itch 
5. SPT – Spontaneous 
6. HZ – Herpes zoster 
7. M – Male 
8. F - Female 
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